PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 25.16

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.27M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-01 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+1.19 (+1.80%)

USD 10.78B
DOCS Doximity Inc

+1.66 (+3.10%)

USD 10.37B
WEAV Weave Communications Inc

+0.26 (+1.66%)

USD 1.13B
MPLN MultiPlan Corporation

+1.26 (+9.73%)

USD 0.12B
AMWL American Well Corp

+0.44 (+6.25%)

USD 0.11B
OWLT Owlet Inc

+0.15 (+3.41%)

USD 0.08B
TDOC Teladoc Inc

N/A

N/A
FOXO FOXO Technologies Inc.

+0.02 (+6.38%)

N/A
EVH Evolent Health Inc

+0.39 (+3.39%)

N/A
VEEV Veeva Systems Inc Class A

+2.45 (+1.16%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 13.85% 80% B- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.85% 80% B- 61% D-
Trailing 5 Years  
Capital Gain -5.38% 50% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.38% 50% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 11.46% 73% C 68% D+
Dividend Return 11.46% 73% C 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.97% 55% F 14% F
Risk Adjusted Return 17.11% 82% B 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector